Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¿°»öü À̼ö¼º°ú °ü·ÃµÈ ºñÁ¤»óÀû ÀÓ½ÅÀÌ ¿¹»óµÇ´Â ȯÀÚ¿¡¼­ Âø»óÀü À¯ÀüÁø´ÜÀÇ °á°ú Preimplantation Genetic Diagnosis for Aneuploidy Screening in Patients with Poor Reproductive Outcome

´ëÇѺÒÀÓÇÐȸÁö 2006³â 33±Ç 3È£ p.179 ~ 187
±èÁø¿µ, ÀÓõ±Ô, Â÷¼±È­, ¹Ú¼öÇö, ¾ç±¤¹®, ¼ÛÀοÁ, ÀüÁøÇö, ¹Ú¼Ò¿¬, ±Ã¹Ì°æ, °­Àμö,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÁø¿µ ( Kim Jin-Yeong ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø »êºÎÀΰú

ÀÓõ±Ô ( Lim Chun-Kyu ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø ºÒÀÓ¿¬±¸½Ç
Â÷¼±È­ ( Cha Sun-Hwa ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø »êºÎÀΰú
¹Ú¼öÇö ( Park Soo-Hyun ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø »êºÎÀΰú
¾ç±¤¹® ( Yang Kwang-Moon ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ÀϺ´¿ø »êºÎÀΰú
¼ÛÀοÁ ( Song In-Ok ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ÀϺ´¿ø »êºÎÀΰú
ÀüÁøÇö ( Jun Jin-Hyun ) 
Á¦ÀϺ´¿ø »ý½Ä»ý¹°ÇÐ ¹× ºÒÀÓ¿¬±¸½Ç
¹Ú¼Ò¿¬ ( Park So-Yeon ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø À¯ÀüÇÐ ¿¬±¸½Ç
±Ã¹Ì°æ ( Koong Mi-Kyoung ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ÀϺ´¿ø »êºÎÀΰú
°­Àμö ( Kang Inn-Soo ) 
¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ »ï¼ºÁ¦ÀϺ´¿ø »êºÎÀΰú

Abstract

¸ñ Àû: ¹è¾ÆÀÇ ¿°»öü À̼ö¼ºÀº Âø»ó½ÇÆгª ÀÚ¿¬À¯»ê°ú °ü·ÃµÇ¸ç ÀÌ´Â °í·ÉÀ̳ª ºÎºÎÀÇ ¿°»öü ÀÌ»óÀÌ ÀÖ´Â °æ¿ì ±× À§ÇèÀÌ Áõ°¡µÇ¾î ½À°ü¼º À¯»êÀ̳ª ¹Ýº¹ Âø»ó½ÇÆÐ µî ºÒ·®ÇÑ ÀӽŰá°ú¸¦ ÃÊ·¡ÇÑ´Ù. ¿°»öü À̼ö¼º¿¡ ´ëÇÑ Âø»óÀü À¯ÀüÁø´ÜÀº Á¤»ó ¿°»öü¸¦ °®´Â ¹è¾Æ¸¦ ¼±º°ÀûÀ¸·Î
À̽ÄÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ È¯Àڵ鿡¼­ È¿°úÀûÀ¸·Î Àû¿ëµÉ ¼ö ÀÖ´Ù. ÀÌ¿¡ ¿°»öü À̼ö¼º¿¡ ´ëÇÑ Âø»óÀü À¯ÀüÁø´ÜÀÇ ÀÓ»óÀû °á°ú¸¦ ¾Ë¾Æº¸°í ¾î¶°ÇÑ È¯ÀÚ±º¿¡¼­ °¡Àå Å« È¿¿ë¼ºÀ» ¾òÀ» ¼ö ÀÖ´ÂÁö ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

¿¬±¸¹æ¹ý: ÃÑ 42¸íÀÇ È¯ÀÚ¿¡¼­ 77ÁÖ±âÀÇ ¿°»öü À̼ö¼º¿¡ ´ëÇÑ Âø»óÀü À¯ÀüÁø´ÜÀ» ½ÃÇàÇÏ¿´´Ù. ȯÀÚ±ºÀ» ÀûÀÀÁõ¿¡ µû¶ó ¼¼ ±ºÀ¸·Î ³ª´©¾î Á¦ 1±ºÀº 37¼¼ ÀÌ»óÀ̸ç 3ȸ ÀÌ»ó ¹Ýº¹ Âø»ó½ÇÆи¦ º¸ÀÎ °æ¿ì (11¿¹, Æò±Õ ³ªÀÌ 42.2¼¼), Á¦ 2±ºÀº 3ȸ ÀÌ»óÀÇ ½À°ü¼º À¯»ê ¹× ÀÌ Áß 1ȸ ÀÌ»ó ¿°»öü À̼ö¼ºÀ» º¸ÀÎ °æ¿ì (19¿¹, Æò±Õ ³ªÀÌ 38.9¼¼), Á¦ 3±ºÀº ÅÍ³Ê ÁõÈıºÀ̳ª Ŭ¶óÀÎÆçÅÍ ÁõÈıº, 47,XYY µî ¼º¿°»öü ÀÌ»óÀ̳ª ¸ðÀÚÀ̽ÃÁòÀ» °¡Áø ȯÀÚ¿´´Ù (18¿¹, Æò±Õ ³ªÀÌ 29.6¼¼). Âø»óÀü À¯ÀüÁø´ÜÀº Á¦1±º°ú 2±º¿¡¼­´Â 13, 16, 18, 21, X, Y¿°»öü¿¡ ´ëÇÑ FISH¸¦, Á¦ 3±º¿¡¼­´Â X, Y ¹× 18 ¶Ç´Â 17¹ø ¿°»öü¿¡ ´ëÇÑ FISH¸¦ ½ÃÇàÇÏ¿´´Ù.

°á °ú: ÃÑ 530°³ÀÇ ¹è¾Æ¿¡¼­ ÇÒ±¸ »ý°ËÀÌ °¡´ÉÇÏ¿´°í FISH Áø´Ü È¿À²Àº 92.3%¿´´Ù. Á¤»ó ¹è¾ÆÀÇ ºñÀ²Àº °¢ ±º¿¡¼­ 32.5¡¾17.5%, 23.0¡¾21.7%, ¹× 52.6¡¾29.2% (mean ¡¾ SD)¿´À¸¸ç Á¦ 3±º¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù (group II vs. III, p<0.05). ¹è¾Æ À̽ÄÀº 51Áֱ⿡¼­ ½ÃÇàÇÏ¿´À¸¸ç ÀÌ½ÄµÈ ¹è¾ÆÀÇ ¼ö´Â °¢°¢ 3.9¡¾1.5, 1.9¡¾1.1 ¹× 3.1¡¾1.4°³ (mean ¡¾ SD)¿´´Ù. ÀÓ»óÀû ÀÓ½ÅÀ²Àº °¢ ±º¿¡¼­ 0%,
30.0% ¹× 20.0%·Î Á¦ 2±º¿¡¼­ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù (p<0.05). ÀüüÀûÀÎ ÀÓ½ÅÀ²Àº 19.6% (10/51)¿´°í ÀÚ¿¬À¯»êÀ²Àº 20% (2/10)¿´À¸¸ç À¯»êµÈ °æ¿ìÀÇ ¿°»öü´Â Á¤»óÀ̾ú´Ù. ½ÖÅÂ¾Æ 1¿¹¸¦ Æ÷ÇÔÇÏ¿© ÃÑ 9¸íÀÇ Á¤»ó¾Æ°¡ Ãâ»ýµÇ¾úÀ¸¸ç, ¾ç¼ö°Ë»ç·Î Á¤»ó ¿°»öü ÇÙÇüÀ» È®ÀÎÇÏ¿´´Ù.

°á ·Ð: ¿°»öü À̼ö¼º¿¡ ´ëÇÑ Âø»óÀü À¯ÀüÁø´ÜÀº ¿°»öü À̼ö¼º°ú °ü·ÃµÈ ºÒ·®ÇÑ Àӽſ¹ÈÄ°¡ ¿¹»óµÇ´Â ȯÀÚ¿¡¼­ À¯¿ëÇÏ°Ô ÀÌ¿ëµÉ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ À̼ö¼º°ú °ü·ÃµÈ ½À°ü¼º À¯»êÀ̳ª ¼º¿°»öü À̻󿡼­ È¿¿ë¼ºÀÌ ÀÖÀ¸¸ç, ¹Ýº¹ Âø»ó½ÇÆп¡¼­´Â Âø»ó¿¡ °ü·ÃµÇ´Â ´Ù¸¥ ¿øÀεéÀÇ º¹ÇÕÀûÀÎ ¿µÇâÀ¸·Î Å« È¿¿ë¼ºÀÌ ¾ø´Â °ÍÀ¸·Î »ý°¢µÈ´Ù.

Objectives: The risk of aneuploidies of embryos increases in advanced maternal age or parental karyotype abnormality and it results in poor reproductive outcomes such as recurrent spontaneous abortion (RSA) or repeated implantation failure (RIF). Preimplantation genetic diagnosis for aneuploidy screening (PGD-AS) can be applied for better ART outcome by selecting chromosomally normal embryos. The aim of this study is to evaluate the clinical outcome of PGD-AS and which group can get much benefit from PGD-AS among the patients expected to have poor reproductive outcome.

Methods: In 42 patients, 77 PGD cycles were performed for aneuploidy screening. Patients were allocated to 3 groups according to the indication of PGD-AS: group I-patients with old age (¡Ã37) and RIF more than 3 times (n=11, mean age=42.2 yrs.), group II-patients with RSA (¡Ã 3 times) associated with aneuploid pregnancy (n=19, mean age=38.9 yrs.), group III-parental sex chromosome abnormality or mosaicism (n=18, mean age=29.6 yrs.) including Turner syndrome, Klinefelter syndrome and 47,XYY. PGD was performed by using FISH for chromosome 13, 16, 18, 21, X and Y in group I and II, and chromosome X, Y and 18 (or 17) in group III.

Results: Blastomere biopsy was successful in 530 embryos and FISH efficiency was 92.3%. The proportions of transferable embryos in each group were 32.5¡¾17.5%, 23.0¡¾21.7% and 52.6¡¾29.2% (mean ¡¾ SD), respectively, showing higher normal rate in group III (group II vs. III, p<0.05). The numbers of transferred embryos in each group were 3.9¡¾1.5, 1.9 1¡¾ .1 and 3.1¡¾1.4 (mean ¡¾ SD), respectively. The clinical pregnancy rates per transfer was 0%, 30.0% and 20.0%, and it was significantly higher in group II (group I vs. group II, p<0.05). The overall pregnancy rate per transfer was 19.6% (10/51) and the spontaneous abortion rate was 20% (2/10) of which karyotypes were euploid. Nine healthy babies (one twin pregnancy) were born with normal karyotype confirmed on amniocentesis.

Conclusion: Our data suggests that PGD-AS provides advantages in patients with RSA associated with aneuploidy or sex chromosome abnormality, decreasing abortion rate and increasing ongoing pregnancy rate. It is not likely to be beneficial in RIF group due to other detrimental factors involved in implantation.

Å°¿öµå

Âø»óÀü À¯ÀüÁø´Ü;¿°»öü À̼ö¼º;Âø»ó½ÇÆÐ;½À°ü¼º À¯»ê
PGD;Aneuploidy; FISH; RIF; RSA

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS